Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

1.290 -0.070 (-5.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
Via Investor Brand Network
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Via ACCESS Newswire
Firefighters Have an Increased Chance of Having Gene Mutations Associated with Brain Cancer, Study Says
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial
Via Investor Brand Network
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Via ACCESS Newswire
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Via ACCESS Newswire
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
Via ACCESS Newswire
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Via ACCESS Newswire
Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum
Via Investor Brand Network
Scientists Discover ‘Roadmap’ Followed by Aggressive Cancers to Spread
Via Investor Brand Network
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split
Via Investor Brand Network
CNS Pharmaceuticals Announces Reverse Stock Split
Via ACCESS Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
Via ACCESS Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
Study Reveals Insights into How Needed Treatments Can Bypass the Blood-Brain Barrier
Via Investor Brand Network
Chinese Research Team Suggests Common Drug for Blood Pressure Could Treat Invasive Brain Tumor
Via Investor Brand Network
Research Shows Brain Tumors Grow by Hijacking Circadian Clocks
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11
Via Investor Brand Network
AI Model Promises New Way to Detect Brain Malignancies
Via Investor Brand Network
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
Via Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
Via Investor Brand Network
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.